Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LX
Post# of 721
(Total Views: 246)
Posted On: 09/05/2018 7:01:24 PM
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Delivers Nicotine to Brain Faster
- Ability to cross blood brain barrier – now confirmed – is significant for possible treatment of central nervous system diseases
- LXRP may also be able to deliver micro nicotine doses, as per developing FDA policies
- LXRP completes formation of wholly owned subsidiary, Lexaria Nicotine Corp., to better commercialize opportunities
- The company is a technology disrupter and has applied for new U.S. patent on its delivery process; it plans to out-license and develop future products
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has been confirmed in analysis of a second generation lab study on 40 rats to transport 195 percent more nicotine, reaching peak levels at a four times faster rate to brain tissue than controls (http://nnw.fm/6vu3X). Originally, the tests were focused on developing products for nicotine delivery or smoking alternatives (http://nnw.fm/z3Dy1). Now, it appears that the technology could also potentially apply to treatment of nervous system diseases, such as Alzheimer’s.
The blood brain barrier is formed by microvascular endothelial cells, which form a layer or lining inside blood vessels and exist to block circulating toxins or other unwanted substances from entering the brain. It has frustrated medical researchers for years as they’ve attempted to discover effective methods of transporting beneficial drugs into the brain.
The new report confirmed first generation results of in vivo tests on live animals showing that DehydraTECH™ was able to deliver more active pharmaceutical ingredients (APIs) across the brain’s protective blood brain barrier, as reported in an article published by the CFN Media Group (http://nnw.fm/oN1Xp). Because of certain similarities in physical structure between the nicotine molecule and several of the drugs used to treat diseases such as Huntington’s, Parkinson’s, schizophrenia and depression, it is now theorized that DehydraTECH could offer similar delivery advantages.
Conceptually, its rapid and efficient delivery to the brain tissue may allow for smaller micro doses, conforming to newly developing FDA policies, the company said. Smaller doses could satiate cravings for nicotine while simultaneously being less addictive, in harmony with FDA goals of reducing nicotine consumption.
In a news release, Chris Bunka, CEO of LXRP, said, “Lexaria’s DehydraTECH delivery technology continues to demonstrate its superior effectiveness in delivering nicotine without the need for combustion or the need for inhalation whatsoever. Crossing the blood brain barrier is a significant achievement all on its own and this data confirms the outcome of our earlier first-generation test.”
The enhanced delivery of nicotine is also significant because LXRP, through wholly owned subsidiary Lexaria Nicotine Corp., seeks to encourage cigarette smokers to use nicotine sources that do not contribute to lung disease. After its original test, LXRP applied to the USPTO for a new patent. Its IP portfolio already includes patents for oral delivery of vitamins, NSAIDs and all cannabinoids.
Lexaria has roughly 50 patents pending or awarded and will license in any of the 40 countries worldwide where its technology already has a patent or is patent-pending. DehydraTECH™ is its proprietary absorption technology platform. Based in British Columbia, Canada, LXRP is a biotechnology company that out-licenses its disruptive delivery technology, which has shown faster and more effective delivery of cannabinoids and now nicotine.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Ability to cross blood brain barrier – now confirmed – is significant for possible treatment of central nervous system diseases
- LXRP may also be able to deliver micro nicotine doses, as per developing FDA policies
- LXRP completes formation of wholly owned subsidiary, Lexaria Nicotine Corp., to better commercialize opportunities
- The company is a technology disrupter and has applied for new U.S. patent on its delivery process; it plans to out-license and develop future products
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has been confirmed in analysis of a second generation lab study on 40 rats to transport 195 percent more nicotine, reaching peak levels at a four times faster rate to brain tissue than controls (http://nnw.fm/6vu3X). Originally, the tests were focused on developing products for nicotine delivery or smoking alternatives (http://nnw.fm/z3Dy1). Now, it appears that the technology could also potentially apply to treatment of nervous system diseases, such as Alzheimer’s.
The blood brain barrier is formed by microvascular endothelial cells, which form a layer or lining inside blood vessels and exist to block circulating toxins or other unwanted substances from entering the brain. It has frustrated medical researchers for years as they’ve attempted to discover effective methods of transporting beneficial drugs into the brain.
The new report confirmed first generation results of in vivo tests on live animals showing that DehydraTECH™ was able to deliver more active pharmaceutical ingredients (APIs) across the brain’s protective blood brain barrier, as reported in an article published by the CFN Media Group (http://nnw.fm/oN1Xp). Because of certain similarities in physical structure between the nicotine molecule and several of the drugs used to treat diseases such as Huntington’s, Parkinson’s, schizophrenia and depression, it is now theorized that DehydraTECH could offer similar delivery advantages.
Conceptually, its rapid and efficient delivery to the brain tissue may allow for smaller micro doses, conforming to newly developing FDA policies, the company said. Smaller doses could satiate cravings for nicotine while simultaneously being less addictive, in harmony with FDA goals of reducing nicotine consumption.
In a news release, Chris Bunka, CEO of LXRP, said, “Lexaria’s DehydraTECH delivery technology continues to demonstrate its superior effectiveness in delivering nicotine without the need for combustion or the need for inhalation whatsoever. Crossing the blood brain barrier is a significant achievement all on its own and this data confirms the outcome of our earlier first-generation test.”
The enhanced delivery of nicotine is also significant because LXRP, through wholly owned subsidiary Lexaria Nicotine Corp., seeks to encourage cigarette smokers to use nicotine sources that do not contribute to lung disease. After its original test, LXRP applied to the USPTO for a new patent. Its IP portfolio already includes patents for oral delivery of vitamins, NSAIDs and all cannabinoids.
Lexaria has roughly 50 patents pending or awarded and will license in any of the 40 countries worldwide where its technology already has a patent or is patent-pending. DehydraTECH™ is its proprietary absorption technology platform. Based in British Columbia, Canada, LXRP is a biotechnology company that out-licenses its disruptive delivery technology, which has shown faster and more effective delivery of cannabinoids and now nicotine.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)